What is Rubedo Life Sciences?
Rubedo Life Sciences operates as a clinical-stage biotechnology firm dedicated to the discovery and development of therapeutics aimed at maintaining biological youth. By identifying and modulating key biological drivers of aging, the company targets pathological cells that contribute to chronic diseases. Their research-driven approach serves the broader healthcare and pharmaceutical markets, positioning the firm as a leader in the emerging field of longevity science. The company's proprietary platform is designed to translate complex aging biology into actionable medical solutions, bridging the gap between academic research and clinical application.
How much funding has Rubedo Life Sciences raised?
Rubedo Life Sciences has raised a total of $52M across 2 funding rounds:
Angel/Seed
$12M
Series A
$40M
Angel/Seed (2020): $12M with participation from Refactor Capital, Khosla Ventures, Shanda, and Longevity Fund companies
Series A (2024): $40M led by Hevolution Foundation, Ahren Innovation Capital, Khosla Ventures, and R42
Key Investors in Rubedo Life Sciences
Hevolution Foundation
Hevolution Foundation is dedicated to promoting healthier and longer lives for individuals, focusing on aging as a treatable process rather than merely addressing its symptoms.
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies across a broad range of sectors including health and biotechnology.
What's next for Rubedo Life Sciences?
With the successful closure of its latest financing round, Rubedo Life Sciences is poised to scale its clinical operations and expand its therapeutic pipeline. The strategic focus will likely shift toward advancing lead candidates through human trials, validating the efficacy of its proprietary discovery platform in real-world settings. As the company matures, it will continue to navigate the complexities of drug development, leveraging its strong investor base to secure the necessary resources for long-term commercialization and regulatory milestones in the competitive biotechnology landscape.
See full Rubedo Life Sciences company page
